JP3993387B2 - 合成ペプチド免疫原のための免疫刺激因子としての人工的ｔヘルパー細胞エピトープ - Google Patents

合成ペプチド免疫原のための免疫刺激因子としての人工的ｔヘルパー細胞エピトープ Download PDF

Info

Publication number
JP3993387B2
JP3993387B2 JP2000555643A JP2000555643A JP3993387B2 JP 3993387 B2 JP3993387 B2 JP 3993387B2 JP 2000555643 A JP2000555643 A JP 2000555643A JP 2000555643 A JP2000555643 A JP 2000555643A JP 3993387 B2 JP3993387 B2 JP 3993387B2
Authority
JP
Japan
Prior art keywords
peptide
seq
epitope
epitopes
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000555643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002518463A5 (enExample
JP2002518463A (ja
Inventor
イー ワン，チャン
Original Assignee
ユナイティド バイオメディカル インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22279634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3993387(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユナイティド バイオメディカル インコーポレイティド filed Critical ユナイティド バイオメディカル インコーポレイティド
Publication of JP2002518463A publication Critical patent/JP2002518463A/ja
Publication of JP2002518463A5 publication Critical patent/JP2002518463A5/ja
Application granted granted Critical
Publication of JP3993387B2 publication Critical patent/JP3993387B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000555643A 1998-06-20 1999-06-21 合成ペプチド免疫原のための免疫刺激因子としての人工的ｔヘルパー細胞エピトープ Expired - Lifetime JP3993387B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10041298A 1998-06-20 1998-06-20
US09/100,412 1998-06-20
PCT/US1999/013975 WO1999066957A2 (en) 1998-06-20 1999-06-21 Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005000038A Division JP3993605B2 (ja) 1998-06-20 2005-01-04 合成ペプチド免疫原のための免疫刺激因子としての人工的ｔヘルパー細胞エピトープ

Publications (3)

Publication Number Publication Date
JP2002518463A JP2002518463A (ja) 2002-06-25
JP2002518463A5 JP2002518463A5 (enExample) 2005-12-22
JP3993387B2 true JP3993387B2 (ja) 2007-10-17

Family

ID=22279634

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000555643A Expired - Lifetime JP3993387B2 (ja) 1998-06-20 1999-06-21 合成ペプチド免疫原のための免疫刺激因子としての人工的ｔヘルパー細胞エピトープ
JP2005000038A Expired - Lifetime JP3993605B2 (ja) 1998-06-20 2005-01-04 合成ペプチド免疫原のための免疫刺激因子としての人工的ｔヘルパー細胞エピトープ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005000038A Expired - Lifetime JP3993605B2 (ja) 1998-06-20 2005-01-04 合成ペプチド免疫原のための免疫刺激因子としての人工的ｔヘルパー細胞エピトープ

Country Status (13)

Country Link
US (1) US6713301B1 (enExample)
EP (2) EP1089760B1 (enExample)
JP (2) JP3993387B2 (enExample)
CN (1) CN1201819C (enExample)
AT (2) ATE463255T1 (enExample)
AU (1) AU763543B2 (enExample)
BR (1) BRPI9912177B8 (enExample)
CA (1) CA2329772C (enExample)
DE (1) DE69942225D1 (enExample)
DK (2) DK1089760T3 (enExample)
ES (2) ES2346116T3 (enExample)
TW (1) TWI229679B (enExample)
WO (1) WO1999066957A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801722T2 (xx) 1996-03-01 1998-12-21 Novartis Ag Peptit imm�nojenler.
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
EP1159297A2 (en) * 1999-01-11 2001-12-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Hiv related peptides
US6911527B1 (en) 1999-01-11 2005-06-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services HIV related peptides
EP2065052A3 (en) * 2000-08-30 2009-08-19 Pfizer Products Inc. Anti-IgE vaccines
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
CN1747970A (zh) 2003-02-06 2006-03-15 三肽公司 抗原/抗体或配体/受体糖基化的特异性交换剂
US20040202673A1 (en) * 2003-04-08 2004-10-14 Jen-Pin Huang Constructs of branched synthetic peptide immunogens with artificial T helper cell epitopes coupled to B cell epitopes
GB2434367B (en) * 2004-10-05 2010-05-12 Diversa Corp Improved vaccines
AT501621A1 (de) * 2005-03-15 2006-10-15 Mattner Frank Dr Zusammensetzungen zur verwendung bei der vorbeugung und behandlung der alzheimer- erkrankung
JP2008543810A (ja) * 2005-06-14 2008-12-04 サイトス バイオテクノロジー アーゲー 抗原コンジュゲート及びその使用
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
FR2945290A1 (fr) * 2009-05-07 2010-11-12 Maan Zrein Anticorps biomarqueur et dispositif de diagnostic pour la detection de certaines maladies auto-immunes
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9932372B2 (en) * 2010-07-08 2018-04-03 United Biomedical, Inc. Designer peptide-based PCV2 vaccine
KR102190180B1 (ko) 2011-04-15 2020-12-11 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Ｄｎａ 백신
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
BR112014015898B1 (pt) 2011-12-30 2022-04-12 United Biomedical, Inc Composições de vacina para a síndrome reprodutiva e respiratória do suíno (prrs) compreendendo antígeno de peptídeo e uso das referidas composições para preparação de uma vacina para proteção de leitões contra infecção por prrs
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
CN102775478B (zh) * 2012-08-10 2013-06-19 申联生物医药（上海）有限公司 口蹄疫病毒抗原多肽及疫苗
JP6001974B2 (ja) 2012-09-21 2016-10-05 アンジェスＭｇ株式会社 アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン
HUE051277T2 (hu) * 2012-11-16 2021-03-01 United Biomedical Inc Szintetikus peptiden alapuló sürgõsségi vakcina ragadós száj- és körömfájás (FMD) ellen
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US20170216418A1 (en) 2014-07-25 2017-08-03 United Biomedical, Inc. Immunogenic lhrh composition and use thereof in pigs
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN105418738B (zh) * 2015-07-03 2019-04-19 申联生物医药（上海）有限公司 口蹄疫病毒a型抗原多肽、融合抗原多肽及疫苗
CN105176897A (zh) * 2015-07-29 2015-12-23 中国药科大学 一种表达GnRH/M2融合多肽的重组工程菌株及其构建和应用
JP2017141234A (ja) * 2017-03-01 2017-08-17 ユナイテッド・バイオメディカル・インコーポレーテッドＵｎｉｔｅｄ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ ブタ生殖器呼吸器症候群（ｐｒｒｓ）の有効な制御のための合成ペプチドベースのマーカーワクチン及び診断システム
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
CN107703294B (zh) * 2017-10-12 2019-06-04 华派生物工程集团有限公司 一种用于检测鸡血清中cLHRH抗体效价的ELISA方法
US20210079054A1 (en) * 2017-12-11 2021-03-18 Ubi Us Holdings, Llc. Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
CA3093709C (en) 2018-03-16 2024-03-26 Zoetis Services Llc Peptide vaccines against interleukin-31
JP2021523127A (ja) * 2018-05-04 2021-09-02 ユービーアイ アイピー ホールディングスＵｂｉ Ｉｐ Ｈｏｌｄｉｎｇｓ 限られたｔ細胞炎症反応で標的抗体産生を促進する人工的な無差別ｔヘルパー細胞エピトープ
MX2021007446A (es) * 2018-12-19 2021-09-08 United Biomedical Inc Epítopos artificiales promiscuos de linfocitos t colaboradores como estimuladores inmunes para inmunógenos peptídicos sintéticos.
CN117003898B (zh) * 2023-09-27 2023-12-29 贝格探索(成都)科技有限公司 一种lhrh4-crm197-lf多聚重组蛋白及其制备方法和应用
CN118812726B (zh) * 2024-06-26 2025-05-16 西北民族大学 脑心肌炎多抗原表位重组蛋白及其在制备脑心肌炎疫苗中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2921574B2 (ja) 1988-02-01 1999-07-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンの担体分子としてのｔ細胞のエピトープ
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
EP0725838A4 (en) 1993-10-26 1997-02-26 United Biomedical Inc STRUCTURED SYNTHETIC ANTIGAN BANKS AS DIAGNOSTICS, VACCINE AND THERAPEUTIC AGENTS
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
US6107021A (en) * 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
JP2002518033A (ja) * 1998-06-20 2002-06-25 ユナイティド バイオメディカル インコーポレイティド 農場動物の成長促進のための合成ソマトスタチン免疫原

Also Published As

Publication number Publication date
ES2346116T3 (es) 2010-10-08
DE69942225D1 (de) 2010-05-20
ATE510563T1 (de) 2011-06-15
DK2181715T3 (da) 2011-09-05
CA2329772A1 (en) 1999-12-29
EP1089760B1 (en) 2010-04-07
EP2181715B1 (en) 2011-05-25
US6713301B1 (en) 2004-03-30
ATE463255T1 (de) 2010-04-15
HK1143950A1 (en) 2011-01-21
CA2329772C (en) 2011-02-22
BR9912177A (pt) 2001-04-10
EP2181715A1 (en) 2010-05-05
EP1089760A1 (en) 2001-04-11
WO1999066957A2 (en) 1999-12-29
CN1201819C (zh) 2005-05-18
BRPI9912177B8 (pt) 2021-05-25
HK1037860A1 (en) 2002-02-22
AU763543B2 (en) 2003-07-24
JP3993605B2 (ja) 2007-10-17
ES2369055T3 (es) 2011-11-24
BRPI9912177B1 (pt) 2016-07-26
DK1089760T3 (da) 2010-07-19
JP2002518463A (ja) 2002-06-25
TWI229679B (en) 2005-03-21
EP1089760A4 (en) 2005-01-12
CN1306439A (zh) 2001-08-01
AU4580899A (en) 2000-01-10
JP2005112860A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
JP3993605B2 (ja) 合成ペプチド免疫原のための免疫刺激因子としての人工的ｔヘルパー細胞エピトープ
US6228987B1 (en) Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
EP0708656B1 (en) Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
EP1089759B1 (en) Synthetic peptide vaccines for foot-and-mouth disease
US5759551A (en) Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
AU2021201950B2 (en) Immunogenic LHRH composition and use thereof in pigs
JP2002518033A (ja) 農場動物の成長促進のための合成ソマトスタチン免疫原
MXPA00011939A (en) Artificial t helper cell epitopes as immune stimulators for synthetic peptideimmunogens
HK1037860B (en) Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens
HK1143950B (en) Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens
HU210966B (en) Method for the preparation of peptides and veterinary compositions containing them
Wang B cell & T cell epitope orientation and adjuvant-free immunization in synthetic vaccine design
MXPA00011752A (en) Synthetic somatostatin immunogen for growth promotion in farm animals

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040929

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20041012

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20050104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20061219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070418

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070626

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070726

R150 Certificate of patent or registration of utility model

Ref document number: 3993387

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100803

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110803

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110803

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120803

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130803

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term